Table 2 Summary of culture characteristics with rocking motion bioreactors

Hami [98] - 2004

Used^a

CD3 and CD28 beads

Xvivo 15

–

CD3+ T cells from PBMC

–

20

–

Wave Bioreactor System 20XE

–

–

–

Perfusion

Tran [66] - 2007

50

Irradiated PBMCs (APCs)

RPMI

10% FBS; HEPES, GLN and Glucose

CD4+ T cells from PBMC

–

–

Wave bioreactor system 2/10 EH

10–12

0.1

4

Perfusion: Media to keep GLN at 2 mM and glucose > 2 g/L.

Hollyman [99] - 2009

100–500

Pre^b - CD3/CD28 beads

Xvivo 15

5% AB

CD3+ from PBMCs

–

2

–

WAVE EHT Bioreactor

6–15

–

Perfusion: Volume increased over 24 h periods (200–1600 mL/day)

Janas [100] - 2015

20 [ng/mL]

Pre - CD3/CD28 beads

Xvivo 10

5% HS; GLN

T cells from PBMCs

5.0 × 10⁶

–

1000

W25 or W5 Xuri cell expansion system

15

–

6

Perfusion: < 2 × 10⁶ cells/mL–0 mL/day; 2–10 × 10⁶ cells/mL–500 mL/day; 10–15 × 10⁶ cells/mL–750 ml/day; > 15 × 10⁶ cells/mL–1000 mL/day

Vavrova [101] - 2016

20

Pre - Ag-mDCs (APCs); CD3/CD28 beads

RPMI

5% AB; GLN, Ne AAs, BME, Pyruvate

T cells from PBMCs

–

2

–

WAVE bioreactor 2/10 system

6

–

6

Media fed: maintain cell concentration in the 0.5–1 × 10⁶ cells/mL range

O’hanlon [102] - 2017

200

Pre PHA

IMDM

10% AB; GLN and glucose

T cells from PBMCs

2.5–5.0 × 10⁵

2

1000

Wave 2/10 (Xuri W5)

5–10

–

–

Perfusion: Culture days 1–2: 250 mL; Culture days 3–5: 500 mL

 McCartney [57] - 2019

350

–

Xuri T CEM

5% AB

T cells from PBMCs

–

2

1000

Xuri Cell Expansion System

10

–

6

Perfusion: < 2 × 10⁶ cells/mL–0 mL/day; 2–10 × 10⁶ cells/mL–500 mL/day; 10–15 × 10⁶ cells/mL–750 ml/day; > 15 × 10⁶ cells/mL–1000 mL/day

Smith [103] - 2019

200–500

Pre anti CD3/CD28/CD2

Xuri T CEM

5% HS

Tcells from PBMCS

1.0 × 10⁶

2

–

Xuri Cell Expansion System W25

10

–

6

Perfusion: < 2 × 10⁶ cells/mL–0 mL/day; 2–10 × 10⁶ cells/mL–500 mL/day; 10–15 × 10⁶ cells/mL–750 ml/day; > 15 × 10⁶ cells/mL–1000 mL/day

Sutlu [94] - 2010

500

OKT3

SCGM

5% HS

PMBC

2.0 × 10⁶

–

from 800

Wave Bioreactor System 2/10

6

0.1

6

Media fed: 300 mL/day when 3 e6 cells/mL when 7 e6 cells/mL, 500 mL/day; 1 e7 cells/mL, 750 mL/day; 2.5 e7, 1 L/day.

Spanholtz [104] - 2011

Used^a

GM-CSF. G-CSF, IL-6, IL-7, IL-15

GBGM

10% HS

CD34+ UCB

1.0 × 10⁶

–

from 250

WAVE Bioreactor System 2/10 and BIOSTATH CultiBag RM

10

0.1–0.2

6

Media addition to adjust cell density

 Rujkijyanont [105] - 2013

500

CD56- (APCs); IL15 OKT3

SCGM

5% AB

CD56+ from PBMCs

1.0 × 10⁶

2–20

from 200

WAVE Bioreactor

5–9

–

–

Media addition to adjust cell density

Lapteva [106] - 2014

500

K562-41BBL-mbIL-15 (APCs)

SCGM

10% FBS

CD56+ from PBMCs

2.0 × 10⁵

–

–

WAVE Bioreactor

6

–

6

–

Meng [97] - 2018

Used^a

Pre OK-432

Xvivo 15

1% AP

PBMC

–

3

3000

GE Xuri W25

7

–

6

Perfusion (parameters not specified)

Sadeghi [107] - 2011

600

PBMCs (APCs); OKT3

RPMI

5% AB; GLN 12 mM, 25 mM HEPES; BME

TIL

5–10.0 × 10⁷ (TOTAL)

2

1000

Wave Bioreactor System 2/10 (GE)

10

–

6

Perfusion: 350–1000 mL/day to maintain glucose and GLN in a range of 1.5–2 g/L and ~ 2–4 mM, respectively.

 Somerville [64] - 2012

3000

Pre – allogenic APCs, anti-CD3

AIMV

5% AB; 0,02% pluronic

TIL/PBL

–

–

1500

WAVE bioreactor 2/10 system

7

–

6

Perfusion: maintain glucose concentration at ~ 170 mg/dL.

Donia [108] - 2014

6000

Pre - allogeneic APCs, antiCD3

AIMV

Pluronic

TIL

–

10

WAVE bioreactor 2/10 system

10

0.2

6

1000–4000 mL/day